Pseudovirus News and Research

RSS
Mechanistic insights into engineered ACE2 receptor traps

Mechanistic insights into engineered ACE2 receptor traps

12 Aug 2022
Bispecific antibody exhibits high breadth and potency against SARS-CoV-2 Omicron sub-lineages

Bispecific antibody exhibits high breadth and potency against SARS-CoV-2 Omicron sub-lineages

12 Aug 2022
The features of the newly emerging SARS-CoV-2 Omicron BA.2.75 subvariant

The features of the newly emerging SARS-CoV-2 Omicron BA.2.75 subvariant

10 Aug 2022
Antibody evasion of Omicron BA.2.75 is less pronounced than BA.4/5

Antibody evasion of Omicron BA.2.75 is less pronounced than BA.4/5

9 Aug 2022
What is the impact of SARS-CoV-2 Omicron BA.2 breakthrough infection on novel Omicron sublineages?

What is the impact of SARS-CoV-2 Omicron BA.2 breakthrough infection on novel Omicron sublineages?

8 Aug 2022
Gut microbiota-derived metabolites offer protection against SARS-CoV-2

Gut microbiota-derived metabolites offer protection against SARS-CoV-2

5 Aug 2022
A combined influenza and COVID-19 mRNA vaccine

A combined influenza and COVID-19 mRNA vaccine

3 Aug 2022
Study suggests peimine may be a potent inhibitor of SARS-CoV-2 variant infection

Study suggests peimine may be a potent inhibitor of SARS-CoV-2 variant infection

2 Aug 2022
How and when do de novo SARS-CoV-2 spike mutations emerge?

How and when do de novo SARS-CoV-2 spike mutations emerge?

1 Aug 2022
ViruStop, ACROBiosystems’s new brand accelerating the process of vaccine development and approval

ViruStop, ACROBiosystems’s new brand accelerating the process of vaccine development and approval

From ACROBiosystems 1 Aug 2022
Study finds asymptomatic SARS-CoV-2 infection induced comparable memory B cell responses to mild symptomatic infection in young adults

Study finds asymptomatic SARS-CoV-2 infection induced comparable memory B cell responses to mild symptomatic infection in young adults

29 Jul 2022
Weak antibody response yet robust cellular immunity identified in children after SARS-CoV-2 Omicron infection

Weak antibody response yet robust cellular immunity identified in children after SARS-CoV-2 Omicron infection

28 Jul 2022
The identification and characterization of an anti-SARS-CoV-2 monoclonal antibody with superior breadth and potency

The identification and characterization of an anti-SARS-CoV-2 monoclonal antibody with superior breadth and potency

28 Jul 2022
Study shows the emerging Omicron sublineage BA.2.75 does not show greater immune evasion than BA.5

Study shows the emerging Omicron sublineage BA.2.75 does not show greater immune evasion than BA.5

27 Jul 2022
Bivalent mRNA vaccine induces powerful antibody response to SARS-CoV-2 Omicron subvariants

Bivalent mRNA vaccine induces powerful antibody response to SARS-CoV-2 Omicron subvariants

25 Jul 2022
Researchers report the detection of viral mutations associated with drug resistance in patients treated with REGEN-COV and sotrovimab

Researchers report the detection of viral mutations associated with drug resistance in patients treated with REGEN-COV and sotrovimab

20 Jul 2022
Study shows Omicron BA.4/5 infection triggers highly cross-reactive neutralizing antibodies

Study shows Omicron BA.4/5 infection triggers highly cross-reactive neutralizing antibodies

20 Jul 2022
The potential of circular RNA COVID-19 vaccines

The potential of circular RNA COVID-19 vaccines

17 Jul 2022
Study provides detailed understanding of SARS-CoV-2 Omicron sublineage antibody escape

Study provides detailed understanding of SARS-CoV-2 Omicron sublineage antibody escape

13 Jul 2022
Research assesses antigenic co-evolution of SARS-CoV-2 variants

Research assesses antigenic co-evolution of SARS-CoV-2 variants

8 Jul 2022

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback